Future Path 529 Plan - Future Path 529 Aggressive Portfolio Fund (FPAHX)
| Fund Assets | n/a |
| Expense Ratio | n/a |
| Min. Investment | n/a |
| Turnover | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | n/a |
| Previous Close | 14.12 |
| YTD Return | 12.92% |
| 1-Year Return | n/a |
| 5-Year Return | n/a |
| 52-Week Low | 11.80 |
| 52-Week High | 14.16 |
| Beta (5Y) | n/a |
| Holdings | n/a |
| Inception Date | n/a |
About FPAHX
Fidelity Select Pharmaceuticals Portfolio is a sector-focused mutual fund designed to capture opportunities in the global pharmaceutical industry. Its primary objective is capital appreciation, typically investing at least 80% of its assets in companies involved in the research, development, manufacture, sale, or distribution of pharmaceuticals and related drugs. The fund primarily holds common stocks of both domestic and international issuers, utilizing fundamental analysis to assess company financials, industry position, and broader market conditions. Notable features of this portfolio include a concentrated exposure to large-cap pharmaceutical leaders, with a significant portion of assets in top global firms such as Eli Lilly, Novo Nordisk, and AstraZeneca. The fund is classified within the health sector and operates as a non-diversified fund, allowing it to take larger positions in fewer companies relative to more broadly diversified funds. With a modest expense ratio and a sizable asset base, the Fidelity Select Pharmaceuticals Portfolio plays a specialized role in the market for investors seeking targeted exposure to the innovative and resilient pharmaceutical sector.